{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-044547","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.451858+00:00","generated_at":"2026-05-30T07:22:20.706703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M","bullets":["IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.","XPHOZAH Q3 net sales $51.5M (+39% QoQ); strong launch continues.","Total revenue $98.2M (up 74% YoY); net loss $0.8M vs net income $6.6M in Q3 2023.","Cash $190.4M at Sep 30; drew $49.7M from SLR loan (SOFR+4.02%) in October.","Appointed Eric Foster as CCO in August; CMS Part D change for XPHOZAH cited as 2025 headwind."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-044547","json":"https://secwatch.observer/filing/0001628280-24-044547.json","markdown":"https://secwatch.observer/filing/0001628280-24-044547.md","text":"https://secwatch.observer/filing/0001628280-24-044547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024044547/0001628280-24-044547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024044547/ardx-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:22:20.706703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}